van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. - In primary analysis of the TRAIN-2 study, high pathologic complete response rates were identified following neoadjuvant chemotherapy with or without anthracyclines plus dual ERBB2 (formerly HER2) blockade. Researchers sought to report the 3-year efficacy and safety results of the regimen for stage II and III ERBB2-positive breast cancer. This randomized, clinical, open-label phase 3 trial was performed across 37 hospitals in the Netherlands from December 9, 2013, until January 14, 2016 including a total of 438 patients with stage II and III ERBB2-positive breast cancer. Outcomes revealed similar 3-year event-free survival estimates of 93% in patients treated with anthracyclines and 94% in patients treated without anthracyclines. The anthracycline group had more frequent decline in left ventricular ejection fraction and there were 2 patients treated with anthracyclines having development of acute leukemia. The results thereby support omission of anthracyclines in early-stage ERBB2-positive breast cancer.